KRAS and neoplasm: However, the one-size-fits-all approach in looking for suitable PDAC biomarkers has been paralleled by approaches looking for multiple alterations, as done by targeting KRAS (and other) mutations in circulating tumor DNA coupled with the assessment of thresholded proteins [98,99].